FAMOSAN 10MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

famosan 10mg potahovaná tableta

pro.med.cs praha a.s. array - 9064 famotidin - potahovaná tableta - 10mg - famotidin

FAMOSAN 20MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

famosan 20mg potahovaná tableta

pro.med.cs praha a.s. array - 9064 famotidin - potahovaná tableta - 20mg - famotidin

FAMOSAN 40MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

famosan 40mg potahovaná tableta

pro.med.cs praha a.s. array - 9064 famotidin - potahovaná tableta - 40mg - famotidin

QUAMATEL 20MG Prášek a rozpouštědlo pro injekční/infuzní roztok Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

quamatel 20mg prášek a rozpouštědlo pro injekční/infuzní roztok

gedeon richter plc., budapešť array - 9064 famotidin - prášek a rozpouštědlo pro injekční/infuzní roztok - 20mg - famotidin

RANISAN 150MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ranisan 150mg potahovaná tableta

pro.med.cs praha a.s. ČeskÁ republika - 4191 ranitidin-hydrochlorid - potahovaná tableta - 150mg - ranitidin

RANISAN 75MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ranisan 75mg potahovaná tableta

pro.med.cs praha a.s. ČeskÁ republika - 4191 ranitidin-hydrochlorid - potahovaná tableta - 75mg - ranitidin

Zitac vet 100 mg tablety pro psy 100 mg Tableta Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

zitac vet 100 mg tablety pro psy 100 mg tableta

intervet international, b.v. - cimetidin - tableta - 100mg - lÉkŮ pro ŽaludeČnÍho vŘedu a refluxnÍ choroba jÍcnu (gord) - psi

Pregabalin Zentiva Evropská unie - čeština - EMA (European Medicines Agency)

pregabalin zentiva

zentiva, k.s. - pregabalin - anxiety disorders; epilepsy - antiepileptika, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Evropská unie - čeština - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotické činidla - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.